SETD3

Across TCGA pan-cancer cohorts, SETD3 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SETD3’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SETD3 RNA is repressed in tumor relative to normal tissue. In most cancer types SETD3 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

THCA, LUAD, and READ are the cancer types where SETD3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SETD3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	III,IV	−0.592	<.001	11	view →
LUAD	Female	II,III,IV	−0.636	<.001	9	view →
READ	All	All	−0.613	<.001	7	view →
KIRP	Male	All	−0.497	.001	7	view →
UCEC	All	All	−0.689	<.001	6	view →
LIHC	All	II,III,IV	+0.400	.002	6	view →
KIRC	Male	II,III,IV	−0.370	<.001	6	view →
KICH	Male	III,IV	−1.059	.004	5	view →
LUSC	Female	All	−0.482	<.001	5	view →
COAD	All	All	−0.277	.009	4	view →
CHOL	All	II,III,IV	+0.940	.024	2	view →
HNSC	Female	III,IV	+0.572	.036	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SETD3–THCA

Open the THCA breakdown →